Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolgolimab in advanced melanoma (FLAT)
NCT05783882Phase 3Unknown
- Sponsor
- BIOCAD
- Start
- Feb 2022
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of prolgolimab in melanoma, sponsored by BIOCAD. Primary endpoint: Overall Response Rate at 6 months. Status: unknown.
02
Drugs
prolgolimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05783882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05783882.